Skip to main content

Advertisement

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Article metrics

The original article was published in Arthritis Research & Therapy 2019 21:54

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1843-9

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error.

Incorrect spelling:

Loreno Dagna

Correct spelling:

Lorenzo Dagna

The original article [1] has been updated.

Reference

  1. 1.

    Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54 https://doi.org/10.1186/s13075-019-1843-9.

Download references

Author information

Correspondence to Giulio Cavalli.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark